274 related articles for article (PubMed ID: 33933153)
21. Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.
Ratajska M; Matusiak M; Kuzniacka A; Wasag B; Brozek I; Biernat W; Koczkowska M; Debniak J; Sniadecki M; Kozlowski P; Klonowska K; Pilyugin M; Wydra D; Laurent G; Limon J; Irminger-Finger I
Oncol Rep; 2015 Nov; 34(5):2609-17. PubMed ID: 26329992
[TBL] [Abstract][Full Text] [Related]
22. BARD1 is necessary for ubiquitylation of nucleosomal histone H2A and for transcriptional regulation of estrogen metabolism genes.
Stewart MD; Zelin E; Dhall A; Walsh T; Upadhyay E; Corn JE; Chatterjee C; King MC; Klevit RE
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):1316-1321. PubMed ID: 29367421
[TBL] [Abstract][Full Text] [Related]
23. BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
Randall MP; Egolf LE; Vaksman Z; Samanta M; Tsang M; Groff D; Evans JP; Rokita JL; Layeghifard M; Shlien A; Maris JM; Diskin SJ; Bosse KR
J Natl Cancer Inst; 2024 Jan; 116(1):138-148. PubMed ID: 37688570
[TBL] [Abstract][Full Text] [Related]
24. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Shakya R; Szabolcs M; McCarthy E; Ospina E; Basso K; Nandula S; Murty V; Baer R; Ludwig T
Proc Natl Acad Sci U S A; 2008 May; 105(19):7040-5. PubMed ID: 18443292
[TBL] [Abstract][Full Text] [Related]
25. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
27. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
28. Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks.
Lee C; Banerjee T; Gillespie J; Ceravolo A; Parvinsmith MR; Starita LM; Fields S; Toland AE; Parvin JD
Hum Mutat; 2015 Dec; 36(12):1205-14. PubMed ID: 26350354
[TBL] [Abstract][Full Text] [Related]
29. HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
Wu W; Togashi Y; Johmura Y; Miyoshi Y; Nobuoka S; Nakanishi M; Ohta T
Cancer Sci; 2016 Oct; 107(10):1406-1415. PubMed ID: 27399284
[TBL] [Abstract][Full Text] [Related]
30. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
Peng Y; Liao Q; Tan W; Peng C; Hu Z; Chen Y; Li Z; Li J; Zhen B; Zhu W; Li X; Yao Y; Song Q; Liu C; Qi X; He F; Pei H
Nat Commun; 2019 Mar; 10(1):1224. PubMed ID: 30874560
[TBL] [Abstract][Full Text] [Related]
31. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
Layman RM; Arun B
Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Wiener D; Gajardo-Meneses P; Ortega-Hernández V; Herrera-Cares C; Díaz S; Fernández W; Cornejo V; Gamboa J; Tapia T; Alvarez C; Carvallo P
Breast Cancer Res Treat; 2015 Oct; 153(3):669-78. PubMed ID: 26395808
[TBL] [Abstract][Full Text] [Related]
34. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Reid LJ; Shakya R; Modi AP; Lokshin M; Cheng JT; Jasin M; Baer R; Ludwig T
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20876-81. PubMed ID: 19088202
[TBL] [Abstract][Full Text] [Related]
35. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
36. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.
Woditschka S; Evans L; Duchnowska R; Reed LT; Palmieri D; Qian Y; Badve S; Sledge G; Gril B; Aladjem MI; Fu H; Flores NM; Gökmen-Polar Y; Biernat W; Szutowicz-Zielińska E; Mandat T; Trojanowski T; Och W; Czartoryska-Arlukowicz B; Jassem J; Mitchell JB; Steeg PS
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24948741
[TBL] [Abstract][Full Text] [Related]
37. RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage.
Krais JJ; Wang Y; Patel P; Basu J; Bernhardy AJ; Johnson N
Nat Commun; 2021 Aug; 12(1):5016. PubMed ID: 34408138
[TBL] [Abstract][Full Text] [Related]
38. BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
Śniadecki M; Brzeziński M; Darecka K; Klasa-Mazurkiewicz D; Poniewierza P; Krzeszowiec M; Kmieć N; Wydra D
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114377
[TBL] [Abstract][Full Text] [Related]
39. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
40. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Laufer M; Nandula SV; Modi AP; Wang S; Jasin M; Murty VV; Ludwig T; Baer R
J Biol Chem; 2007 Nov; 282(47):34325-33. PubMed ID: 17848578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
